Clinical Trials Browser

Phase 1/2 × lenvatinib × 90 days × Clear all

NCT04300556 2026-06-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04938817 2026-06-01

KEYNOTE-B98

Phase 1/2 Active not recruiting

110 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04305054 2026-05-28

KEYMAKER-U02

Phase 1/2 Completed

335 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05319730 2026-05-26

MK-3475-06B

Phase 1/2 Recruiting

230 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04626479 2026-05-18

MK-3475-03A

Phase 1/2 Active not recruiting

400 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04977453 2026-05-15

Keynote B59

Phase 1/2 Recruiting

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT06110793 2026-05-13

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase 1/2 Recruiting

54 enrolled

Breast

Breast Neoplasms

NCT04626518 2026-05-06

KEYMAKER-U03

Phase 1/2 Active not recruiting

370 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06253494 2026-04-09

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Phase 1/2 Recruiting

60 enrolled

Gynecologic

Endometrial Neoplasms

NCT07096609 2026-04-03

LONGIST

Phase 1/2 Recruiting

48 enrolled

Sarcoma

GIST

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

170 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Phase 1/2 Active not recruiting

301 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms